StreetSmart Live! Presents Michael Ballanger on 10/26/2020. Learn More

Sector Expert: Brandon Primack

SeeThruEquity

Image: Brandon Primack

Brandon Primack, senior equity research analyst with SeeThruEquity, has more than 15 years of experience in the asset management business with a focus on equity research and portfolio management. Prior to joining SeeThruEquity, Primack founded Primack Capital LLC, where he ran a structured derivative product and provided asset allocation consulting services to high net-worth individuals. Prior to that, Primack spent seven years at Allianz Global Investors, where he served as a senior equity research analyst covering healthcare and industrials for large- and mid-cap growth-oriented products. He also served as a quantitative analyst in Allianz's Structured Product Group, which focused on enhanced derivative products. Primack received his master's degree in business administration (finance) from New York University's Stern School of Business, and his bachelor's degree in economics from the University of Michigan. He has been a CFA charterholder since 2004.



Recent Interviews

Huge Growth Delivered in Very Small Packages: SeeThruEquity's Ajay Tandon and Brandon Primack (10/30/14)
moneygiftbox580

Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very small companies. The paradox: The micro-cap space is where investors can find the tenbaggers. That disconnect and its attendant irony are not lost on SeeThruEquity's Ajay Tandon and Brandon Primack. In this interview with The Life Sciences Report, Tandon and Primack discuss four companies nurturing seeds of dramatic growth that could materialize in the wake of upcoming catalysts.

X-Ray Vision or Due Diligence? How SeeThruEquity Analysts Find Hidden Small-Cap Biotech Plays (5/1/14)

SeeThruEquity stays an arm's length away from the small biotech firms it analyzes for investors, but gets intimate enough to discover firms that hold promise. In this interview with The Life Sciences Report, senior analyst Brandon Primack and the firm's CEO, Ajay Tandon, explain why they find this handful of small biotechs intriguing.

Recent Quotes

"We find CTH to be a very compelling story."

The Life Sciences Report Interview with Brandon Primack (10/30/14)
more >

"The combination of DMPI's VAL-083 and radiation therapy showed an immediate survival benefit in glioblastoma multiforme."

The Life Sciences Report Interview with Brandon Primack (10/30/14)
more >

"CTH's film strip for apomorphine is a tremendous leap forward in technology."

The Life Sciences Report Interview with Brandon Primack (5/1/14)
more >

"DMPI is breaking new ground and reporting positive topline data for VAL-083."

The Life Sciences Report Interview with Brandon Primack (5/1/14)
more >



Due to permission requirements, not all quotes are shown.